SOX2 and neoplasm: In CRC, SOX2 overexpression has been associated with tumor progression and disease recurrence and SOX2 de novo expression was associated with poorly differentiated and more invasive tumors and poor patient overall survival (Lundberg et al., 2014; Lundberg et al., 2016).